http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Lipid-Drug Conjugates: Innovation and Applications highlights the most recent advances and clinical applications of nano lipid-drug conjugates for enhanced drug delivery and targeting in the treatment of cancer, glioblastoma, Alzheimer's, AIDS, and bacterial diseases. In addition, various conjugation methods to prepare lipid-drug conjugates and their pharmacokinetics in vivo are explored, together with the production and characterization of various delivery carriers for lipid-drug conjugates. The contents of this book provide pharmaceutical science researchers with the tools to explore targeted drug delivery leveraging the unique characteristics of lipid conjugates. Scientists in the corporate setting can benefit of the cases and techniques presented in developing new formulations and products.- Introduces the principles, methods and therapeutic benefits of lipid-drug conjugates- Summarizes recent scientific progress and novel applications of nano lipid-drug conjugates- Provides supportive clinical evidence for several applications.
Front Cover -- Lipid-Drug Conjugates: Innovation and Applications -- Copyright Page -- Contents -- List of contributors -- Preface -- 1 Innovations in lipid-drug conjugates -- 1 Lipid-drug conjugates: application of lipid in drug delivery -- 1.1 Introduction -- 1.2 The concept of lipid-drug conjugates -- 1.3 Various lipid moieties used in lipid-drug conjugate designing -- 1.3.1 Fatty acids -- 1.3.2 Glycerides -- 1.3.3 Phospholipids -- 1.3.4 Steroids -- 1.3.5 Fat-soluble endogenous molecules -- 1.4 Method of preparation -- 1.4.1 Lipid-drug conjugates with noncovalent linkages -- 1.4.2 Lipid-drug conjugates with covalent linkages: without spacer -- 1.4.3 Lipid-drug conjugates with covalent linkages: with spacer -- 1.5 Incorporation of lipid-drug conjugates in delivery systems -- 1.5.1 High-pressure homogenization -- 1.5.2 Microemulsion technique -- 1.5.3 Solvent emulsification evaporation -- 1.5.4 Solvent emulsification-diffusion -- 1.6 Delivery system for lipid-drug conjugates -- 1.6.1 Liposomes -- 1.6.2 Emulsions -- 1.6.3 Micelles -- 1.6.4 Lipid nanoparticles -- 1.6.5 Polymeric nanoparticles -- 1.7 Advantages of lipid-drug conjugates -- 1.7.1 Targeted drug delivery -- 1.7.2 Enhancement of oral bioavailability -- 1.7.3 Overcoming drug resistance -- 1.7.4 Achieving extended drug release -- 1.7.5 Enhance tumor targeting and reduce toxicity -- 1.8 Applications of lipid-drug conjugates -- 1.9 Conclusion and future perspective -- References -- 2 Lipid-drug conjugates: conjugation methods and therapeutic benefits -- 2.1 Introduction -- 2.2 Lipid-drug conjugation methods -- 2.2.1 Lipid-drug conjugates with covalent bonds -- 2.2.1.1 Lipid-drug conjugates through covalent bonds without spacer -- 2.1.1.1 Conjugation through Ester bonds -- 2.1.1.2 Conjugation through Hydrazone bonds -- 2.1.1.3 Conjugation through amide bonds.
2.1.1.4 Conjugation through disulfide bonds -- 2.2.1.2 Lipid-drug conjugates through covalent bonds with spacer/linker -- 2.2.2 Lipid-drug conjugates with non-covalent bonds -- 2.3 Therapeutic benefits of lipid-drug conjugates -- 2.3.1 Low-density lipoproteins-assisted targeted drug delivery -- 2.3.2 Low-density lipoproteins-assisted tumor targeting and reduce toxicity -- 2.3.3 Low-density lipoproteins for countering drug resistance -- 2.3.4 Low-density lipoproteins for oral drug bioavailability enhancement -- 2.3.5 Low-density lipoproteins for boosting pharmacological activity -- 2.4 Current status quo on clinical trials of lipid-drug conjugates -- 2.5 Conclusion and future perspectives -- References -- Further reading -- 3 Route of administration and cellular interaction of lipid drug conjugates -- 3.1 Introduction -- 3.2 Delivery system of lipid drug conjugations -- 3.2.1 Emulsion -- 3.2.2 Liposomes -- 3.2.3 Micelles -- 3.2.4 Lipid nanoparticles -- 3.2.5 Polymeric nanoparticles -- 3.3 Routes of administration -- 3.3.1 Oral -- 3.3.1.1 Lipid-drug conjugation approaches for oral lipid-drug conjugates -- 3.3.1.2 Mechanisms involved in enhancing oral bioavailability of oral lipid-drug conjugates -- 3.3.1.3 Therapeutic utilities of oral lipid-drug conjugates -- 3.3.2 Intravenous -- 3.3.2.1 Therapeutic utilities of intravenous lipid-drug conjugates -- 3.3.3 Subcutaneous -- 3.3.3.1 Therapeutic utilities of subcutaneous lipid drug conjugations -- 3.4 Cellular interaction of lipid drug conjugates -- 3.4.1 Cellular uptake by interacting with lipids -- 3.4.2 Cellular uptake by interacting with proteins in cell membrane -- 3.4.3 Cellular uptake of saccharides located in cell membrane -- 3.4.4 Through disulfide exchange -- 3.5 Conclusion -- References -- 4 Lipid-drug conjugates for enhanced drug delivery and targeting -- 4.1 Introduction.
4.2 Lipid-drug conjugate -- 4.3 Selection of drugs, lipids, solvents, and possible linkers in the formulation of lipid-drug conjugates -- 4.4 Application of lipid-drug conjugates: a flourishing approach for enhanced drug targeting -- 4.4.1 Enhancing oral drug delivery -- 4.4.1.1 Leveraging lipid metabolism pathways -- 4.4.1.2 Enhanced cell membrane interaction -- 4.4.2 Improve the delivery of anticancer drugs -- 4.4.2.1 Enhanced tumor targeting -- 4.4.2.2 Controlled release in the tumor microenvironment -- 4.4.2.3 Reduced toxicity of anticancer drugs -- 4.4.3 Overcoming drug resistance -- 4.4.4 Enhancing central nervous system drug delivery with lipid-drug conjugates -- 4.4.4.1 Increasing lipophilicity -- 4.4.4.2 Receptor-mediated transport -- 4.4.5 Enhancing delivery of gene medicines with lipid-drug conjugates -- 4.4.5.1 Role of lipid-drug conjugates in gene medicine delivery -- 4.4.5.2 Lipid-mediated small interfering RNA delivery -- 4.5 Mechanism of drug release from lipid-drug conjugates -- 4.5.1 pH-responsive lipid-drug conjugates -- 4.5.2 Enzyme-responsive lipid-drug conjugates -- 4.5.3 Redox-responsive lipid-drug conjugates -- 4.5.4 Reactive oxygen species-responsive lipid-drug conjugates -- 4.6 Conclusion and future perspectives -- Acknowledgment -- Conflict of interest -- References -- Further reading -- 5 Antibody-conjugated lipid nanoparticles as a targeted drug delivery system for hydrophobic drugs -- 5.1 Introduction -- 5.2 Hydrophobic drugs and their delivery challenges -- 5.2.1 Techniques for solubility enhancement of hydrophobic drugs -- 5.3 Lipid nanoparticles, and antibodies as targeting agents -- 5.3.1 Liposome -- 5.3.2 Solid lipid nanoparticles -- 5.3.3 Nanostructured lipid carriers -- 5.3.4 Lipid-polymer hybrid nanoparticles -- 5.3.5 Nanoemulsions -- 5.3.6 Lipid drug conjugates nanoparticles -- 5.3.7 Transferosomes.
5.4 Antibodies as targeting agents -- 5.4.1 Overview of antibody structure and function -- 5.4.2 Design for antibody-targeted nanoparticles -- 5.5 Conjugation techniques for ACNP production -- 5.5.1 Adsorption -- 5.5.2 Binding by adapter molecules -- 5.5.3 Covalent strategies -- 5.5.4 Carbodiimide chemistry -- 5.5.5 Maleimide chemistry -- 5.5.6 Click chemistry -- 5.5.7 Multivalent effect of antibody-conjugated nanoparticles -- 5.6 Challenges in the development of ACNPs for medical use -- 5.7 Diagnostic applications of ACNPs -- 5.7.1 In vitro diagnostic applications -- 5.7.1.1 Cell sorting -- 5.7.1.2 Sensing -- 5.7.2 In vivo diagnostic applications -- 5.7.2.1 Imaging -- 5.7.2.2 Therapeutic applications -- 5.7.2.2.1 Targeted drug delivery -- 5.7.2.2.2 Tumor therapy -- 5.7.2.2.3 Brain targeting -- 5.7.2.2.4 Gene delivery and tissue repair -- 5.7.2.2.5 Inflammatory and infectious diseases -- 5.7.2.2.6 Pulmonary diseases -- 5.7.2.2.7 Other applications -- 5.8 Future perspectives -- 5.9 Conclusion -- Author contributions -- Declaration of competing interest -- Acknowledgments -- References -- 6 Pharmacokinetics of lipid drug conjugates -- 6.1 Introduction -- 6.2 Structural features, conjugation methods, and delivery carriers -- 6.2.1 Different types of conjugation strategies -- 6.2.1.1 Phospholipid conjugation -- 6.2.1.2 Glyceride conjugation -- 6.2.1.3 Fatty acid conjugation -- 6.2.1.4 Steroid conjugation -- 6.3 Pharmacokinetics of lipid drug conjugates -- 6.3.1 Absorption and permeation -- 6.3.2 Distribution -- 6.3.2.1 Mechanism of drug distribution and metabolism in lipid drug conjugates -- 6.3.2.2 Factors influencing distribution -- 6.3.2.2.1 Physicochemical properties -- 6.3.2.2.2 Biological factors -- 6.3.2.2.3 Effect of bonds -- 6.3.2.2.4 Effect of composition -- 6.3.3 Metabolism -- 6.3.3.1 Hydrolysis -- 6.3.3.2 Redox reactions -- 6.3.3.3 Transport.
6.3.4 Clearance and elimination of lipid drug conjugates -- 6.3.4.1 Clearance kinetics -- 6.4 Clinical implications of lipid drug conjugates and its challenges -- 6.5 Conclusion and future directions -- References -- 7 Production and characterization of various delivery carriers for lipid-drug conjugates -- 7.1 Introduction -- 7.2 Delivery carries of lipid-drug conjugates -- 7.2.1 Emulsion -- 7.2.2 Liposome -- 7.2.3 Niosome -- 7.2.4 Polymeric nanoparticles -- 7.2.5 Polymeric micelles -- 7.2.6 Solid lipid nanoparticle -- 7.2.7 Nanostructured-lipid carrier -- 7.2.8 Carbon nanotubes -- 7.2.9 Mesoporous silica nanoparticle -- 7.3 Production method of lipid-drug conjugate loaded delivery carriers -- 7.3.1 High pressure homogenization -- 7.3.2 Microemulsion technique -- 7.3.3 Solvent emulsification-evaporation -- 7.3.4 Solvent emulsification-diffusion -- 7.3.5 Solvent injection -- 7.3.6 Thin film hydration -- 7.3.7 Wet milling -- 7.4 Characterization of lipid-drug conjugates loaded delivery carrier -- 7.4.1 Fourier transformed infrared spectra analysis -- 7.4.2 Mass spectroscopy -- 7.4.3 Nuclear magnetic resonance -- 7.4.4 Particle size -- 7.4.5 Polydispersity index -- 7.4.6 Zeta potential -- 7.4.7 Electron microscopy analysis -- 7.4.8 Crystal structure study -- 7.4.8.1 X-ray powder diffraction analysis -- 7.4.8.2 Differential scanning calorimetry -- 7.4.9 Fluorescence spectroscopy -- 7.4.10 Entrapment efficiency and drug loading -- 7.4.11 In vitro drug release and release kinetic assessment -- 7.4.12 Stability testing -- 7.5 Mechanism of drug release from lipid-drug conjugates based carriers -- 7.6 Clinical aspects of lipid-drug conjugates based drug development -- 7.7 Patent review on lipid-drug conjugates -- 7.8 Regulatory aspects of lipid-drug conjugate nanocarriers -- 7.9 Conclusion -- References -- 2 Applications of lipid-drug conjugates.
Systèmes d'administration de médicaments